|
|
PARD3 |
par-3 family cell polarity regulator |
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- Tight junction interactions
|
|
|
|
|
PAX6 |
paired box 6 |
- Regulation of gene expression in beta cells
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
- Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Formation of the anterior neural plate
|
|
- Ocular coloboma, including: Coloboma of iris choroid and retina (COI); Coloboma of optic nerve (COLON)
- Aniridia
- Polymicrogyria; Bilateral frontal polymicrogyria (BFP); Bilateral frontoparietal polymicrogyria (BFPP); Bilateral perisylvian polymicrogyria (BPP); Bilateral parasagittal parieto-occipital polymicrogyria (BPOP); Bilateral generalised polymicrogyria (BGP); Unilateral Polymicrogyria (ULP)
|
|
|
PCM1 |
pericentriolar material 1 |
- Regulation of PLK1 Activity at G2/M Transition
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Anchoring of the basal body to the plasma membrane
- AURKA Activation by TPX2
|
|
|
|
|
PFKM |
phosphofructokinase, muscle |
|
|
- Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
|
|
|
PFKP |
phosphofructokinase, platelet |
|
|
|
|
|
PKIA |
cAMP-dependent protein kinase inhibitor alpha |
|
- 3,5-Diiodotyrosine
- Hydroxyfasudil
- (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
- (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE
- (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
- (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE
- N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
- 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE
- (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
- (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- H-89
- 5-(2-methylpiperazine-1-sulfonyl)isoquinoline
- N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE
- 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
- 3-pyridin-4-yl-1H-indazole
- 5-benzyl-1,3-thiazol-2-amine
- 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
- 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium
- Fasudil
- Myristic acid
- A-674563
- 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE
- Y-27632
|
|
|
|
PKIB |
cAMP-dependent protein kinase inhibitor beta |
|
|
|
|
|
PKIG |
cAMP-dependent protein kinase inhibitor gamma |
|
|
|
|
|
POLH |
DNA polymerase eta |
- Translesion Synthesis by POLH
- Termination of translesion DNA synthesis
- HDR through Homologous Recombination (HRR)
|
|
- Disorders of nucleotide excision repair, including: Xeroderma pigmentosum (XP); Cockayne syndrome (CS); UV-sensitive syndrome (UVS); Trichothiodystrophy (TTD); Cerebro-oculo-facio-skeletal syndrome (COFS); XFE progeroid syndrome
|
|
|
PPP3R2 |
protein phosphatase 3 regulatory subunit B, beta |
|
|
|
|
|
RAB4A |
RAB4A, member RAS oncogene family |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Synthesis of PIPs at the plasma membrane
- TBC/RABGAPs
- RAB geranylgeranylation
- MET receptor recycling
|
|
|
|
|
RACK1 |
receptor for activated C kinase 1 |
- Regulation of TNFR1 signaling
- TNFR1-induced NF-kappa-B signaling pathway
- TNFR1-mediated ceramide production
- Degradation of CDH1
|
|
|
|
|
RASGRP4 |
RAS guanyl releasing protein 4 |
- FCERI mediated NF-kB activation
- RAF/MAP kinase cascade
|
|
|
|
|
REDIC1 |
regulator of DNA class I crossover intermediates 1 |
|
|
|
|
|
RGS2 |
regulator of G protein signaling 2 |
- G alpha (q) signalling events
|
|
|
|
|
SHROOM3 |
shroom family member 3 |
|
|
|
|
|
SLC13A1 |
solute carrier family 13 member 1 |
- Sodium-coupled sulphate, di- and tri-carboxylate transporters
|
|
|
|
|
SMCP |
sperm mitochondria associated cysteine rich protein |
|
|
|
|
|
TERT |
telomerase reverse transcriptase |
- Telomere Extension By Telomerase
- Formation of the beta-catenin:TCF transactivating complex
- Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
|
- Zidovudine
- Grn163l
- Tertomotide
|
- Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
|
|
|
THAP10 |
THAP domain containing 10 |
|
|
|